ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma
Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
ETOP 15-19 ABC-lung is an international, multi-centre open-label, randomized phase II trial
with two non-comparative parallel arms of atezolizumab plus bevacizumab with
carboplatin-paclitaxel (Arm A) or atezolizumab, bevacizumab and pemetrexed (Arm B) in
patients with stage IIIB-IV non-squamous non-small cell lung cancer (NSCLC) harbouring EGFR
mutations after failure of standard EGFR tyrosine kinase inhibitors (TKIs).